Fintel reports that on April 2, 2025, Redburn Atlantic initiated coverage of Quest Diagnostics (NYSE:DGX) with a Buy ...

Redburn Atlantic analyst Jamie Clark initiated coverage of Quest Diagnostics (DGX) with a Buy rating and $195 price target Don't Miss Our End ...

This was the stock's second consecutive day of gains.

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...

Thrivent Financial for Lutherans decreased its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 7.1% ...

With a market cap of $18.5 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

Quest Diagnostics (NYSE:DGX – Get Free Report) had its price objective lifted by equities researchers at Robert W. Baird from $190.00 to $191.00 in a note issued to investors on Thursday,Benzinga ...

Quest Diagnostics logged a -1.0% change during today's afternoon session, and is now trading at a price of $166.27 per share.

Analysts have set 12-month price targets for Quest Diagnostics, revealing an average target of $179.44, a high estimate of ...

Baird raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $190 and keeps an Outperform rating on the shares. The firm ...

Shares of Quest Diagnostics (NYSE: NYSE:DGX) tumbled 4.75% today after the company provided long-term guidance that failed to meet investor expectations. Despite reaffirming its full-year 2025 ...